.
New Delhi, April 26 (MondayMirror.com) The Drugs Controller General of India (DCGI) on Tuesday approved the restricted emergency use authorisation (EUA) to Bharat Biotech’s Covaxin for children between the age of 6-12 years, sources said.
The DGCI has asked vaccine manufacturer to submit safety data including the data on adverse event with due analysis every 15 days for the first two months and monthly thereafter upto 5 months, said the source familiar with the development.
This development comes after the Subject Expert Committee (SEC) discussed recommendations for the restricted emergency use of Covaxin in children aged between 2-12 years.
However, the SEC, after a meeting on Thursday, had recommended restricted emergency use of Biological E’s Covid-19 vaccine, Corbevax, in children aged 5-12 years.
Source: IANS
To make a wave in the digital entertainment world, a new OTT platform, Oceaniek Stream,…
Punjab Governor & Administrator Chandigarh (UT) Gulab Chand Kataria inaugurates event India's leading industry body,…
A protest was organized by members of the Chandigarh wheelchair cricket team and residents ,…
The 10th GTA Cup Open National Taekwondo Championship, organized by Emerald Martial Arts Academy, successfully…
As we step into 2025, the world of OTT entertainment continues to deliver thrilling and…
Bollywood, the heart of India’s entertainment industry, has been shaped by its music just as…